Chronic Hepatitis B and HIV Coinfection: a Continuing Challenge in the Era of Antiretroviral Therapy

被引：11
作者：
H. Nina Kim
机构：
[1] Infectious Diseases, University of Washington, 325 Ninth Avenue, Seattle, 98104, WA
[2] Center for AIDS Research, University of Washington, Seattle, WA
来源：
Current Hepatology Reports | 2020年 / 19卷 / 4期
关键词：
Coinfection; Hepatitis B; Human immune deficiency virus (HIV);
D O I：
10.1007/s11901-020-00541-x
中图分类号：
学科分类号：
摘要：
Purpose of Review: The burden of chronic hepatitis B (HBV) remains disproportionately high among people living with HIV (PLWH) despite the advent of HBV vaccination and HBV-active antiretroviral therapy (ART). This review summarizes new insights and evolving issues in HIV-HBV coinfection. Recent Findings: HBV-HIV coinfection is still a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality more than a decade after the approval of tenofovir. While tenofovir-based ART has been shown to improve rates of HBV virologic suppression and halt fibrosis progression, the long-term benefits on the prevention of end-stage liver disease or HCC in HIV-HBV coinfection have yet to be convincingly demonstrated in PLWH. Missed opportunities for HBV vaccination persist despite evidence of ongoing risk for HBV infection in this population. Summary: Even as we work towards HBV elimination and functional cure, ongoing efforts should focus on optimizing risk stratification as well as uptake of HBV-active antiviral therapy and HBV immunization in this priority population. © The Author(s) 2020.
引用
收藏
页码：345 / 353
页数：8
相关论文
共 76 条
[1]  
. Global hepatitis report, (2017)
[2]  
Platt L., French C.E., McGowan C.R., Sabin K., Gower E., Trickey A., Et al., Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis, J Viral Hepat, 27, pp. 294-315, (2020)
[3]  
Kourtis A.P., Bulterys M., Hu D.J., Jamieson D.J., HIV-HBV coinfection--a global challenge, N Engl J Med, 366, pp. 1749-1752, (2012)
[4]  
Chun H.M., Fieberg A.M., Hullsiek K.H., Lifson A.R., Crum-Cianflone N.F., Weintrob A.C., Ganesan A., Barthel R.V., Bradley W.P., Agan B.K., Landrum M.L., Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years, Clin Infect Dis, 50, pp. 426-436, (2010)
[5]  
Spradling P.R., Richardson J.T., Buchacz K., Moorman A.C., Brooks J.T., Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007, J Viral Hepat, 17, pp. 879-886, (2010)
[6]  
Roberts H., Kruszon-Moran D., Ly K.N., Hughes E., Iqbal K., Jiles R.B., Holmberg S.D., Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012, Hepatology, 63, pp. 388-397, (2016)
[7]  
Puoti M., Torti C., Bruno R., Filice G., Carosi G., Natural history of chronic hepatitis B in co-infected patients, J Hepatol, 44, pp. S65-S70, (2006)
[8]  
Colin J.F., Cazals-Hatem D., Loriot M.A., Martinot-Peignoux M., Pham B.N., Auperin A., Et al., Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men, Hepatology, 29, pp. 1306-1310, (1999)
[9]  
Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoz A., Et al., HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS), Lancet, 360, pp. 1921-1926, (2002)
[10]  
Sikavi C., Chen P.H., Lee A.D., Saab E.G., Choi G., Saab S., Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population, Hepatology, 67, pp. 847-857, (2018)
12345678